Unit
- Regenerative medicine: A multidisciplinary field focused on repairing, replacing, or regenerating damaged tissues and organs. It includes cell therapies, gene therapies, and tissue engineering approaches. Operations professionals must understand these modalities to design effective workflows.
- Cell therapy: Involves administering living cells to patients to restore function. Common cell types include stem cells and immune cells. Manufacturing requires strict aseptic processing and quality control.
- Gene therapy: Delivers genetic material into cells to correct or modify gene expression. Operations must handle viral vectors with specialized cold chain and biocontainment.
- Tissue engineering: Combines cells, scaffolds, and growth factors to create functional tissue constructs. Operations face challenges in scaffold sourcing, bioreactor scaling, and sterility assurance.
- Stakeholder landscape: Includes researchers, clinicians, regulators, payers, manufacturers, and patients. Effective communication across these groups is critical for successful operations.
- Operational lifecycle: From donor sourcing and cell processing to final release and patient administration. Each step demands coordination between manufacturing, quality, and clinical teams.
- Unique challenges: Autologous therapies are patient-specific, requiring individualized supply chains. Allogeneic therapies face inventory management of off-the-shelf products with limited shelf life.
- Quality by design: Emphasizes building quality into processes rather than testing products at the end. Operational teams apply risk management and process validation to ensure consistent product quality.
Scope of Practice
Role: Regenerative Medicine Operations Manager
Within scope:
- Overseeing manufacturing schedules and resource allocation
- Establishing standard operating procedures for cell processing
- Coordinating with quality assurance for batch release
- Managing cold chain logistics for cryopreserved products
- Training staff on regulatory requirements and good manufacturing practices
Outside scope:
- Performing cell culture or vector production directly
- Prescribing therapies or determining patient eligibility
- Altering approved protocols without quality change control
- Setting pricing or reimbursement strategies unilaterally
- Conducting clinical research without oversight
Quick Revision
- Regenerative medicine includes cell, gene, and tissue engineering therapies.
- Operations must address unique challenges such as autologous supply chains and viral vector handling.
- Stakeholders include researchers, clinicians, regulators, payers, manufacturers, and patients.
- Quality by design and risk management are foundational operational principles.